Last reviewed · How we verify
SHR-A2102 for Injection
SHR-A2102 for Injection is a monoclonal antibody targeting PD-1.
SHR-A2102 for Injection is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | SHR-A2102 for Injection |
|---|---|
| Sponsor | Shanghai Hengrui Pharmaceutical Co., Ltd. |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, SHR-A2102 for Injection blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby promoting an anti-tumor immune response. This mechanism is thought to enhance the body's ability to recognize and attack cancer cells. The exact molecular details of this interaction are complex and involve multiple protein domains.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
- A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer (PHASE3)
- A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer (PHASE1, PHASE2)
- Phase II Clinical Study of SHR2554 Tablets Combined With Other Anti-tumor Treatments in Non-small Cell Lung Cancer Subjects (PHASE2)
- A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma (PHASE3)
- SHR-A2102 Combined With Adebrelimab as Neoadjuvant Therapy for Early Triple-Negative Breast Cancer (PHASE2)
- Clinical Study on the Treatment of MIBC Patients With SHR-A2102 Injection Combined With Adebrelimab (SHR-1316) (PHASE2, PHASE3)
- A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors (PHASE2)
- A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Esophageal Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR-A2102 for Injection CI brief — competitive landscape report
- SHR-A2102 for Injection updates RSS · CI watch RSS
- Shanghai Hengrui Pharmaceutical Co., Ltd. portfolio CI